REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
23/06/2025
Voltar para busca
Dado oficial do USPTO
DRUGOME
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
DRUGOME
ST13
US500000088397912Classe
9, 35, 36, 42
Pedido
88397912
Registro
6083085
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
24/06/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
9, 35, 36, 42
Data de depósito
23/04/2019
Data de registro
23/06/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/06/2020
Última transação
24/06/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
OSAKA, JP
Examinador
SMITH, BRIDGETT
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
SUMITOMO PHARMA CO. LTD.
SUMITOVANT BIOPHARMA, INC.
Roivant Sciences GmbH
Representantes
B. Brett Heavner Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Classificação técnica
Classes Nice
Classe 9Classe 35Classe 36Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 9
Downloadable computer software for providinganalyzing and generating reports; downloadable computer software for data processing; downloadable computer software for the capturecollectionconversionanalysiscommunicationprocessingreceivingrecordingstorage and/or transmission of dataimages and information; downloadable computer software for the conversionanalysisprocessingstorage and transmission of artificial intelligence; downloadable computer software for database integration; downloadable computer software for creating searchable databases of information and data; downloadable software for analytics in the fields of healthcarepharmaceuticalsbiomedicinepharmaceutical and biomedical research and developmentfor clinical trial and post-market trial data; downloadable computer software featuring electronic computer databases of pharmaceuticalsbiomedical researchfor clinical trial and post-market trial data; downloadable computer search engine software for compilingaccessing and providing updated scientificmedicalpharmaceutical and clinical informationnews information of general interest
Classe 35
Advertising; business management; business administration; office functions; business research services in the field of healthcarepharmaceuticalsbiomedicinepharmaceutical and biomedical research and developmentclinical trialspost-market data; business information services; market research; provision of market research information; data processing services; analysis of business data; business analysis and statistical analysis of healthcare datapharmaceuticalsbiomedical researchfor clinical trial and post-market data; systematization and compilation of data in computer databasesin particular compilation of information into computer databases for research and analysis purposes in the field of healthcarepharmaceuticalsbiomedicinepharmaceutical and biomedical research and developmentclinical trials and post-market data; professional business analysis and consultancy and statistical analysis in the fields of healthcarepharmaceuticalsbiomedicineclinical trialsepidemiological researchpharmacoepidemiological researchpost-market trials and research evaluating epidemiological outcomes
Classe 36
Financial analysis; financial consulting; financial valuations and forecasting; financial analysiscompiling and analyzing statistics and data; financial analysis of investments in pharmaceutical and biomedical research and developmentclinical and post-market trials; financial evaluationtrackinganalysisforecastingconsultancyadvisory and research services relating to healthcarepharmaceuticalsbiomedicinepharmaceutical and biomedical research and developmentclinical and post-market trials
Classe 42
Scientific and technological servicesscientific research and analysis in the field of pharmaceuticals and biomedicine; analysis of technical data by computers; pharmaceuticalbiomedicalbiological therapeutic research services; research in the field of pharmaceutical and biologic therapeutic preparations; pharmaceutical and biopharmaceutical research and development; providing scientific research information in the field of pharmaceuticalsbiomedicineclinical trials and post-market trials; cloud computing featuring software for conducing scientific research and analysis in the fields of public healthhealthcarepharmaceutical and biomedical researchclinical trial data and data from examinations carried out after the introduction of medicines on the market; providing temporary use of online non-downloadable computer software featuring electronic computer databases of pharmaceuticalsbiomedicinepharmaceutical and biopharmaceutical research and developmentmedical informationclinical trial and post-market trial data; providing temporary use of online non-downloadable computer software for research in the field of pharmaceuticals and biopharmaceuticals; providing temporary use of online non-downloadable computer software for compilingaccessingcontrollingmanaging and providing updated scientificpharmaceuticalmedical and clinical informationnews information of general interest; Artificial intelligence and machine learning statistical analysisconsultancy and reporting for pharmaceutical and biomedical research; information of general interest; providing temporary use of non-downloadable software applications accessible via a web site for data analyticsfinancial analytics and risk management for use in the fields of pharmaceutical and biomedical research and developmentclinical trialsthe provision of medical and healthcare services
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
24/01/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/09/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/09/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/09/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/09/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/09/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
23/06/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/04/2020
PUBO
PUBLISHED FOR OPPOSITION
07/04/2020
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
25/03/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/03/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/03/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
25/02/2020
ALIE
ASSIGNED TO LIE
25/02/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
25/02/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
25/02/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
25/02/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
10/02/2020
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
04/02/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
21/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/12/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/12/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/12/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/06/2019
GNRT
NON-FINAL ACTION E-MAILED
11/06/2019
CNRT
NON-FINAL ACTION WRITTEN
11/06/2019
DOCK
ASSIGNED TO EXAMINER
03/06/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/05/2019
NWAP
NEW APPLICATION ENTERED
26/04/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace DRUGOME ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.